Status:
UNKNOWN
Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation
Lead Sponsor:
Dr. Soetomo General Hospital
Conditions:
Supraspinatus Tear
Eligibility:
All Genders
35-75 years
Phase:
NA
Brief Summary
This is a non-randomized clinical trial conducted in a single tertiary hospital which investigates the efficacy of allogeneic adipose-derived mesenchymal stem cells and human amniotic membrane (AAdMSC...
Detailed Description
Supraspinatus tendon tear is the most common factor causing shoulder pain, mainly resulting in discomfort and functional deficit in individuals over the age of 35. Supraspinatus tendon repair surgery ...
Eligibility Criteria
Inclusion
- Suffering from complete/total tear of supraspinatus tendon for a duration of fewer than 12 months
- Diagnosis is established based on clinical condition and ultrasonography or MRI examination
Exclusion
- Patients with comorbid diseases: Diabetes Mellitus, Rheumatoid Arthritis, and other inflammatory diseases.
- Patients presenting with other related injuries, such as fractures or dislocation around the shoulder joint.
Key Trial Info
Start Date :
October 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04670302
Start Date
October 17 2019
End Date
December 31 2022
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga
Surabaya, East Java, Indonesia, 60286